NCT06265688

First In Human Study of CX-2051 in Advanced Solid Tumors

An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: CytomX Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.

Detailed description

The study is comprised of 2 parts. Part 1 involves CX-2051 dose escalation to identify the maximum tolerated dose (MTD) of CX-2051 as monotherapy and as combination therapy (CX-2051 combined with bevacizumab). Part 2 (dose expansion) will further assess safety and tolerability as well as preliminarily assess antitumor activity of CX-2051 as monotherapy and/or combination therapy in indication-specific expansion cohorts.

Conditions

• Solid Tumor, Adult

Interventions

Type	Name	Description
DRUG	CX-2051	Investigational drug
DRUG	Bevacizumab	IV infusion

Timeline

• Start date: 2024-04-02
• Primary completion: 2027-11-30
• Completion: 2029-03-31
• First posted: 2024-02-20
• Last updated: 2026-03-25

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study